Table 1

NY-ESO-1 serum and urine antibody status in patients with advanced NY-ESO-1+ cancersa.

Patient Primary Cancer Metastases Serum Ab Urine Ab
NW29 melanoma lymph nodes ++ +
NW923 urothelial liver ++ +
NW1073 soft tissue sarcoma liver ++ +
NW1106 melanoma lung, lymph nodes ++ +
NW1123 breast lung, liver ++ +
NW1231 thyroid pleura ++ +
NW1288 stomach liver ++ +
NW1310 breast brain, bone ++ +
NW1418 breast skin, lung ++ +
NW1453 melanoma lymph nodes ++ +
NW1474 leiomyosarcoma peritoneum ++ +
NW1496 multiple myeloma bone ++ +
NW1539 melanoma brain, lymph node ++ +
NW1558 ovary peritoneum ++ +
NW1567 ovary peritoneum ++ +
NW1620 soft tissue sarcoma peritoneum ++ +
NW1622 NSCLC liver ++ +
NW1624 stomach lymph nodes ++ +
NW1714 prostate bone ++ +
NW1715 NSCLC lung, lymph nodes ++ +
NW1716 ovary peritoneum ++ +
NW1241 NEC liver + -
NW1312 NHL lymph nodes + -
NW1366 ovary peritoneum + -
NW1374 SCLC lung + -
NW1621 NSCLC lung + -
NW1717 prostate bone + -
NW1718 NSCLC pleura, lung + -
NW475 melanoma lymph nodes - -
NW555 melanoma liver, lung - -
NW597 melanoma bone - -
NW846 soft tissue sarcoma lymph nodes, bone - -
NW886 melanoma lung - -
NW1045 melanoma lung - -
NW1071 NSCLC lung - -
NW1189 breast lymph nodes - -
NW1409 CAC liver - -
NW1431 prostate bone - -
NW1439 prostate bone - -
NW1451 NSCLC lung - -
NW1497 melanoma lung, lymph nodes - -
NW1719 prostate bone - -
NW1720 soft tissue sarcoma peritoneum - -
NW1721 melanoma lung - -
NW1722 NSCLC lung - -
NW1723 NSCLC lung - -
NW1724 melanoma brain, bone - -

aSera were analyzed for the presence of NY-ESO-1 antibody by Western blotting at dilutions ranging from 1:250 to 1:10,000. Antibody reactivity was considered strong (++) when detectable at a serum dilution of 1:10,000, weak (+) when detectable at a serum dilution 1:250, and negative (-) when no reactivity was detected. Urine samples were assessed at dilutions ranging from 1:1 to 1:1,000 for the presence of NY-ESO-1 antibody. Antibody reactivity was considered positive (+) when detectable at a urine dilution of 1:100 and negative (-) when no reactivity was detected in the undiluted sample. Abbreviations: NSCLC, non-small cell lung cancer; NEC, neuro-endocrine carcinoma; NHL, non-Hodgkin's lymphoma; SCLC, small cell lung cancer; CAC, cholangiocellular carcinoma.